Format

Send to

Choose Destination
Cancer Treat Rev. 2017 Jul;58:61-69. doi: 10.1016/j.ctrv.2017.06.003. Epub 2017 Jun 23.

Targeting STAT3 with silibinin to improve cancer therapeutics.

Author information

1
Medical Oncology, Catalan Institute of Oncology, Girona, Catalonia, Spain; Girona Biomedical Research Institute (IDIBGI), Girona, Catalonia, Spain; Department of Medical Sciences, Medical School, University of Girona, Girona, Spain. Electronic address: jbosch@iconcologia.net.
2
Medical Oncology, Catalan Institute of Oncology, Girona, Catalonia, Spain; Girona Biomedical Research Institute (IDIBGI), Girona, Catalonia, Spain; Department of Medical Sciences, Medical School, University of Girona, Girona, Spain.
3
Girona Biomedical Research Institute (IDIBGI), Girona, Catalonia, Spain; ProCURE (Program Against Cancer Therapeutic Resistance), Metabolism & Cancer Group, Catalan Institute of Oncology, Girona, Catalonia, Spain.

Abstract

Signal transducer and activator of transcription 3 (STAT3) has a prominent role in mediating resistance to conventional chemo-/radio-therapies and modern targeted drugs. While a number of STAT3 inhibitors have been shown to enhance the efficacy of therapeutic agents in vitro, the majority of them have yet to enter clinical evaluation mostly because of lack of efficacy issues. Silibinin is the main component of the silymarin complex, a standardized extract obtained from the seeds of the milk thistle herb Silybum marianum. This review summarizes current evidence supporting the ability of silibinin to function as a natural down-modulator of STAT3 activity. We examine the reported capacity of silibinin to reduce the toxicity of cancer treatments and to reverse tumor cell resistance via STAT3 inhibition. We also briefly review our clinical data in cancer patients treated with oral nutraceutical products containing silibinin. The beneficial effects of silibinin might accelerate the design of strategies aimed to overcome and prevent the emergence of STAT3-mediated cancer drug resistance in clinical settings.

KEYWORDS:

Cancer; Chemotherapy; LegasilĀ®; Radiotherapy; STAT3; Silibinin

PMID:
28686955
DOI:
10.1016/j.ctrv.2017.06.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center